NCT03271983已完成早期 1 期
Evaluation of the Bioavailability of Metronidazole Dermal Products
适应症
干预措施
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- PK Parameters
研究概览
简要总结
Generate human PK data by collecting data following the application of metronidazole formulations.
详细描述
This research study is intended to develop models for in vitro/in vivo correlation (IVIVC) of drug absorption from dermal products. This study will use metronidazole products that have already been approved by the Food and Drug Administration (FDA) and are already sold to customers in the United States; will not include any placebos.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or non-pregnant, women who are of any ethnic background between the age of 18 to 45 years old
- •Subjects must be non-smokers/tobacco users (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
- •Provide written informed consent before initiation of any of the study procedures
- •Agree not to participate in another clinical trial/study during the study period or to participate in an investigational drug study for at least 1 month after the last study session
- •Able to adhere to the study protocol and study restrictions
- •Able to participate in all study sessions
- •Subjects have upper arms large enough to allow for placement of 200 cm2 [31 in2] area for applications of gel or cream. The arm distance from the greater tubercle to the olecranon process should be a minimum of 30 cm. The circumference of the upper arms should be a minimum of 30 cm.
- •Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
- •Negative urine drug screening test (cannabinoids, amphetamines, barbiturates, benzodiazepine, cocaine, methadone, opiates, PCP)
- •Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate aminotransferase (AST)
- •Have normal screening laboratories for urine protein and urine glucose
- •Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year), or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of each study session, and must agree to use reliable hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner
- •Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study session
- •Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
- •Have normal vital signs:
- •Temperature 35-37.9°C (95-100.3°F)
- •Systolic blood pressure 90-165 mmHg
- •Diastolic blood pressure 60-100 mmHg
- •Heart rate 55-100 beats per minute
- •Respiration rate 12-20 breaths per minute
- •Exclusion criteria:
- •Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of any study session
- •Smokers/tobacco users (current use or use over the previous 2 months of nicotine-containing substances (e.g., cigarettes, cigars, chewing tobacco, gum, snuff, patch or electronic cigarettes)
- •Current participation in any ongoing investigational drug trial/study or clinical drug trial/study
- •History as either reported by the subject or evident to the investigator of infectious disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic dermatitis)
- •History of diabetes
- •History of significant skin cancers (e.g., melanoma, squamous cell carcinoma) except basal cell carcinomas that were superficial and did not involve the investigative sites
- •Body Mass Index (BMI) ≥30 kg/m2
- •History of chronic obstructive pulmonary disease or cor pulmonale, or substantially decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression
- •Active positive Hepatitis B, C and/or HIV test results
- •Positive urine drug screening test
- •Use of chronic prescription medications during the period 0 to 30 days; or over-the-counter medications (e.g. antihistamines, topical corticosteroids) and short term (<30 days) prescription medications during the period 0-3 days before a study session (vitamins, herbal supplements and birth control medications not included)
- •Currently taking daily anticoagulants (warfarin, heparin, rivaroxaban, dabigatran, etc...) within the past month prior to entry into the study
- •History of blood dyscrasia (abnormal in structure, function and quality)
- •History of Crohn's disease
- •Donation or loss of greater than one pint of blood within 60 days of entry to the study
- •Any prior adverse reaction or hypersensitivity to metronidazole, parabens, other inactive ingredients in the topical gel or cream formulations
- •Received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month before enrollment in this study or expects to receive an experimental agent during the study
- •Consumption (food or drink) of alcohol within 48 h prior to dose administration
- •Any condition that would, in the opinion of the Medically Accountable Investigator (MAI), place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
- •Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application site (upper arms), sunburn, raised moles or scars, open sores at application site (upper arms), scar tissue, tattoo, or coloration that would interfere with placement of metronidazole products, skin assessment, or reactions to metronidazole
排除标准
- 未提供
研究组 & 干预措施
metronidazole gel 1
Other
RLD gel
干预措施: Metronidazole gel 1 (Drug)
metronidazole gel 2
Other
generic gel
干预措施: Metronidazole gel 2 (Drug)
metronidazole cream
Other
generic cream
干预措施: Metronidazole cream (Drug)
结局指标
主要结局
PK Parameters
时间窗: 3 study sessions/subject; each session was 25 h; blood samples obtained at the following time points: -60 min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 23, 24, 25 h; at least one week washout period between each study session
Area under the concentration-time curve from 0 to 25 h
次要结局
未报告次要终点
研究者
Audra Stinchcomb
Professor
University of Maryland, Baltimore
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Relative Bioavailability of of Olodaterol and KetoconazoleHealthyPulmonary Disease, Chronic ObstructiveNCT01153711Boehringer Ingelheim32
已完成
不适用
Population Pharmacokinetics of Metronidazole in NeonatesEmergenciesNCT04031183Rennes University Hospital171
Unknown
4 期
comparison of two different antimicrobial gels either alone or in combination form in patients with gum diseaseCTRI/2018/03/012504Pujan Acharya
进行中（未招募）
4 期
Pharmacokinetics of Transdermal MetronidazoleHealthyNCT05929794University of Iowa24
Unknown
不适用
Amoxicillin and Metronidazole During Periodontal TreatmentChronic PeriodontitisNCT02954393Belén Retamal-Valdes180